Evaluation of Compliance to Clinical, Paraclinical and Therapeutic Follow-Up in Patients with Chronic Hepatitis B Virus at the Yalgado Ouedraogo University Hospital in Ouagadougou
Aims: To evaluate the clinical, paraclinical and therapeutic compliance of patients with chronic hepatitis B virus at the Department of Hepato-Gastroenterology in Yalgado Ouedraogo University Hospital. Patients and Methods: This is a prospective, descriptive and analytical cross-sectional study conducted over a period of 3 months on patients who were chronic carriers of the hepatitis B virus and who had given their consent. Compliance was assessed using the GIRERD adherence assessment test and the visual analogue scale (VAS). Results: A total of 104 patients were included, 61 of whom were men (58.6%). The mean age was 40.2 years with a standard deviation of 12.6 years. Sixty-three patients (60.6%) were treated with tenofovir. Three-quarters of the patients were compliant with their six-monthly clinical follow-up and 25% had adequate paraclinical follow-up. Tenofovir supply disruption was the cause of treatment discontinuation in 30.4% of cases. Factors associated with compliance were female sex, monthly income and age. Factors associated with regularity of the follow-up were distance, higher level of education and being a shopkeeper. Conclusions: Our study showed good compliance to clinical follow-up but an inadequate adherence to paraclinical follow-up. A good understanding of the determinants of compliance is needed to incorporate them into clinical practice to ensure optimal patient care.
References
[1]
Shiha, G., Soliman, R., Hassan, A., Farahat, A., Salem, A., Taha, A., et al. (2024) Management of Patients with CHB Outside the Guidelines: Insights from Egyptian Cohort with Long-Term Follow-Up. Clinical Liver Disease, 23, e0183. https://doi.org/10.1097/cld.0000000000000183
[2]
Zampino, R. (2015) Hepatitis B Virus Burden in Developing Countries. World Journal of Gastroenterology, 21, Article 11941. https://doi.org/10.3748/wjg.v21.i42.11941
WHO (2024) Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection. https://www.who.int/publications/i/item/9789240090903
[5]
Ghany, M.G. (2017) Current Treatment Guidelines of Chronic Hepatitis B: The Role of Nucleos(t)ide Analogues and Peginterferon. Best Practice & Research Clinical Gastroenterology, 31, 299-309. https://doi.org/10.1016/j.bpg.2017.04.012
[6]
Rouillon, F. (2009) Épidémiologie du trouble bipolaire. Annales Médico-Psychologiques, revue psychiatrique, 167, 793-795. https://doi.org/10.1016/j.amp.2009.09.015
[7]
Haynes, R.B., Taylor, D.W. and Sackett, D.L. (1979) Compliance in Health Care. Johns Hopkins University Press.
[8]
Sombié, R., Sangaré, L., Guingané, A., Tiendrébéogo, A., Kaboré, D. and Bougouma, A. (2015) Traitement de l’hépatite B chronique par les analogues de nucléos(t)ides. Journal Africain d’Hépato-Gastroentérologie, 9, 114-118. https://doi.org/10.1007/s12157-015-0601-4
[9]
Anzouan-Kacou, H.Y.K., Dehinsala, M., Bangoura, A.D., Kouamé, D.H., Doffou, A.S., Mahassadi, A.K., et al. (2022) Socio-Economic Aspects of the Management of Chronic Viral Hepatitis in Côte-d’Ivoire. Annales Africaines de Medecine, 15, e4770-e4778. https://doi.org/10.4314/aamed.v15i4.3
[10]
Zohoncon, T.M., Ilboudo, D.P., Dahourou, L., Da, T.R.C.I., Zongo, L. and Simpore, J. (2023) Clinical and Paraclinical Profiling of Patients with Viral Hepatitis B and C Attending Saint Camille Hospital in Ouagadougou (HOSCO). Journal of Biosciences and Medicines, 11, 225-240. https://doi.org/10.4236/jbm.2023.1110021
[11]
Sombié, R., Bougouma, A., Diallo, O., Bonkoungou, G., Cissé, R., Sangare, L., et al. (2010) Hépatite B chronique: Aspects épidémiologique, diagnostique, thérapeutique et évolutif au centre hospitalier universitaire Yalgado Ouédraogo de Ouagadougou. Journal Africain d’Hépato-Gastroentérologie, 4, 3-10. https://doi.org/10.1007/s12157-009-0137-2
[12]
Nguyen, M.H., Wong, G., Gane, E., Kao, J. and Dusheiko, G. (2020) Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clinical Microbiology Reviews, 33, e00046-19. https://doi.org/10.1128/cmr.00046-19
[13]
Mongo-Onkouo, A., Apendi, C.A., Monamou, J.M., Itoua-Ngaporo, N.A., et al. (2019) Coût Financier de la Prise en Charge des Hépatites Virales Chroniques B et C au CHU de Brazzaville (Congo). Health Sciences and Diseases, 20, 46-49.
[14]
UNICEF (2017) Genre et pauvreté au Burkina Faso. https://www.unicef.org/burkinafaso/rapports/genre-et-pauvrete-au-burkina-faso
[15]
Carrieri, P., Cailleton, V., Le Moing, V., Spire, B., Dellamonica, P., Bouvet, E., et al. (2001) The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results from the French National APROCO Cohort. Journal of Acquired Immune Deficiency Syndromes, 28, 232-239. https://doi.org/10.1097/00042560-200111010-00005
Adoubi, K.A., Diby, K.F., Nguetta, R., Yangni-Angate, K.H. and Adoh, A.M. (2006) Facteurs de la mauvaise observance therapeutique de l’hypertendu en Côte d’Ivoire. Revue Internationale des Sciences Médicales, 2006, 1822.
[18]
Malik, S.K., Kouassi, S.E., Adoubi, A.K., Kouamé, J., Acka, F., Bissouma, A.C., et al. (2020) Environnement Familial et Observance du Traitement de l’Hypertension Artérielle dans une Population d’Hypertendus à Abidjan. Health Sciences and Diseases, 21, 68-72.
[19]
Scheen, A.J. and Giet, D. (2010) Non-observance thérapeutique: Causes, conséquences, solutions. Revue Médicale de Liège, 65, 239-245.
[20]
Pourette, D. and Enel, C. (2015) Représentations et vécu de l’hépatite B de patients subsahariens en Côte d’Ivoire et en France. Santé Publique, 26, 869-878. https://doi.org/10.3917/spub.146.0869